D. Western Therapeutics Institute (FRA:6DW) Interest Expense: €-0.03 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6DW D. Western Therapeutics Institute Inc FRA:6DW
30 GF Score
Price €0.40
GF Value €0.34
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is D. Western Therapeutics Institute Interest Expense?

D. Western Therapeutics Institute FRA:6DW 30 Interest Expense is €-0.03 Mil as of Dec. 2025. GuruFocus rates FRA:6DW with a GF Score™ of 30/100 and a GF Value™ of €0.34 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. D. Western Therapeutics Institute's interest expense for the three months ended in Dec. 2025 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.03 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. D. Western Therapeutics Institute's Operating Income for the three months ended in Dec. 2025 was € 0.00 Mil. D. Western Therapeutics Institute's Interest Expense for the three months ended in Dec. 2025 was € 0.00 Mil. GuruFocus does not calculate D. Western Therapeutics Institute's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

D. Western Therapeutics Institute  (FRA:6DW) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

D. Western Therapeutics Institute's Interest Expense for the three months ended in Dec. 2025 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2025 was €0.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2025 was €2.77 Mil.

D. Western Therapeutics Institute's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

GuruFocus does not calculate D. Western Therapeutics Institute's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

D. Western Therapeutics Institute Interest Expense Historical Data

* Premium members only.

The historical data trend for D. Western Therapeutics Institute's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D. Western Therapeutics Institute Interest Expense Chart

D. Western Therapeutics Institute Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.02 -0.02 -0.03 -0.05

D. Western Therapeutics Institute Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 0.00 0.00 -0.02
FRA:6DW
30GF Score
D. Western Therapeutics Institute Inc FRA:6DW
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

D. Western Therapeutics Institute Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.03 Mil mean?
D. Western Therapeutics Institute (FRA:6DW) has a Interest Expense of €-0.03 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on D. Western Therapeutics Institute and its competitors.
Is D. Western Therapeutics Institute's Interest Expense too high?
D. Western Therapeutics Institute's current Interest Expense is €-0.03 Mil. Overall, D. Western Therapeutics Institute has a GF Score™ of 30/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's Interest Expense compare to VRTX and REGN?
D. Western Therapeutics Institute's Interest Expense of €-0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on D. Western Therapeutics Institute and its competitors. D. Western Therapeutics Institute's current Interest Expense is €-0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (FRA:6DW) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.34, compared to a current price of €0.40 — trading 17.1% above its estimated fair value. The current Interest Expense is €-0.03 Mil. D. Western Therapeutics Institute's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For D. Western Therapeutics Institute (FRA:6DW), the current Interest Expense is €-0.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is D. Western Therapeutics Institute (FRA:6DW) Overvalued in 2026?

Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued. The current stock price of €0.40 is trading 17.1% above its estimated GF Value™ of €0.34. GuruFocus considers D. Western Therapeutics Institute to be Modestly Overvalued.

Key valuation signals for FRA:6DW:

  • Interest Expense: €-0.03 Mil
  • GF Value™: €0.34 vs. price of €0.40 (17.1% above fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the FRA:6DW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

D. Western Therapeutics Institute Business Description

Other Exchanges 4576:Japan
Address 7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
30GF Score

Get the complete analysis for FRA:6DW

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.40
Price
€0.34
GF Value